文献速递糖尿病肥胖与代谢综合征

HEXA-FC蛋白治疗增加胰岛素抵抗小鼠和2型糖尿病小鼠模型的骨骼肌葡萄糖摄取并改善血糖控制

HEXA-FC protein therapy increases skeletal muscle glucose uptake and improves glycaemic control in mice with insulin resistance and in a mouse model of type 2 diabetes.
PubMed 文献 · Diabetologia · 2025-03-29

本研究制备长效HEXA-FC融合蛋白(鼠源HEXA与IgG1的FC段),在饮食诱导肥胖伴胰岛素抵抗的C57BL/6小鼠和db/db重度2型糖尿病小鼠模型中,每两周给药一次(1 mg/kg体重),评估其对血糖控制的影响。结果显示慢性给药改善了随机血糖、空腹血糖和葡萄糖耐量,其机制为增加骨骼肌葡萄糖处置并增强肌肉IGF1信号传导。作者认为HEXA-FC蛋白治疗可能为2型糖尿病治疗开辟新途径。

要点

  • HEXA-FC(1 mg/kg,每两周一次)改善饮食诱导肥胖胰岛素抵抗小鼠和db/db小鼠的随机血糖、空腹血糖及葡萄糖耐量。
  • 血糖改善由骨骼肌葡萄糖处置增加驱动,并与肌肉IGF1信号增强相关。
  • 作者认为HEXA-FC蛋白治疗可能为2型糖尿病治疗开辟新途径。

核心结论

  • 鉴于骨骼肌是2型糖尿病患者胰岛素抵抗的主要部位,HEXA-FC蛋白治疗可能为2型糖尿病治疗开辟新途径。

研究设计与样本

  • 制备长效HEXA-FC融合蛋白(鼠源HEXA与IgG1的FC段)。
  • 在饮食诱导肥胖伴胰岛素抵抗的C57BL/6小鼠和db/db重度2型糖尿病小鼠模型中,评估每两周一次慢性给药(1 mg/kg体重)对血糖控制的影响。
  • 结局指标包括葡萄糖和胰岛素耐量试验(含稳定同位素标记的葡萄糖耐量试验和组织特异性葡萄糖处置评估),以及蛋白质组学分析骨骼肌代谢变化。

主要发现

  • 慢性给予长效重组HEXA-FC融合蛋白改善了随机血糖、空腹血糖和葡萄糖耐量。
  • 上述改善由骨骼肌葡萄糖处置增加驱动。
  • 上述效应与肌肉IGF1信号增强相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Type 2 diabetes is a chronic metabolic disorder characterised by insulin resistance and sustained hyperglycaemia, and is a major cause of blindness, kidney failure, heart attacks and stroke. Our team has recently identified hexosaminidase A (HEXA) as an endocrine factor secreted by the liver that regulates sphingolipid metabolism in skeletal muscle. Specifically, HEXA converts GM2 to GM3 gangliosides within cell-surface lipid rafts. Remodelling of ganglioside composition by HEXA enhances IGF1 signalling in skeletal muscle, increasing muscle glucose uptake and improving blood glucose control. METHODS: We produced a long-acting HEXA-FC fusion protein (murine HEXA and the fragment crystallisable [FC] region from IgG1) and evaluated the effects of chronic bi-weekly HEXA-FC administration (1 mg/kg body weight) on glycaemic control in C57BL/6 mice with diet-induced obesity and insulin resistance and the db/db mouse model of severe type 2 diabetes. Outcome measures included glucose and insulin tolerance, including a stable isotope-labelled GTT and assessment of tissue-specific glucose disposal, as well as proteomics analysis to define changes in skeletal muscle metabolism. RESULTS: Chronic administration of a long-acting recombinant HEXA-FC fusion protein led to improvements in random blood glucose, fasting blood glucose and glucose tolerance, driven by increased glucose disposal into skeletal muscle, effects that were associated with enhancement of IGF1 signalling in muscle. CONCLUSIONS/INTERPRETATION: Given that skeletal muscle is a primary site of insulin resistance in individuals with type 2 diabetes, HEXA-FC protein therapy may open new avenues for therapeutic advancement in type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Montgomery MK, Lin S, Yang CH, et al. HEXA-FC protein therapy increases skeletal muscle glucose uptake and improves glycaemic control in mice with insulin resistance and in a mouse model of type 2 diabetes. Diabetologia. 2025. PMID: 40156616. doi:10.1007/s00125-025-06413-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。